| http://www.w3.org/ns/prov#value | - This study is a multi-institution, Phase I/IIa open-label, dose-finding, safety, pharmacokinetics (PK), and proof-of-concept study of GDC-0810 administered orally on a continuous daily dosing regimen with a PK lead-in period (dose escalation period only).
|
